MeSH D009196 - myeloproliferative disorders
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D001855:Bone marrow diseases
D009196:Â
Myeloproliferative disorders
D000750:Myelophthisic anemia
0 Companies
0 Drugs
Success rate
D004915:Erythroblastic leukemia acute
0 Companies
0 Drugs
Success rate
D007955:Leukemoid reaction
0 Companies
0 Drugs
Success rate
D011087:Polycythemia vera
D013922:Thrombocytosis
D015464:Bcr-abl positive chronic myelogenous leukemia
D055728:Primary myelofibrosis
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Novartis | Ruxolitinib | Jakavi |  | 2012-08-23 | $1,828 M | Q2/22-Q2/25 |
| Bristol Myers Squibb | Fedratinib | Inrebic |  | 2021-02-08 | $110 M | Y2023 |
| Endo | Sodium phenylbutyrate | Phenylbutyrate |  | 2016-06-15 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
76%60/79
Phase 2
25%20/79
Phase 3
10%5/50
Approved: 3Overall Success rate: 2%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use